Scope and Claims Analysis of U.S. Patent 11,801,226
What is the scope of U.S. Patent 11,801,226?
U.S. Patent 11,801,226 covers a novel formulation of a small-molecule drug candidate intended for treatment of inflammatory or autoimmune diseases. The patent encompasses composition claims, methods of use, and manufacturing processes. The core of the patent relates to a specific chemical entity, designated as compound X, which exhibits high bioavailability and selectivity for target enzyme Y.
The patent claims a class of compounds derived from compound X, with structural modifications such as substitutions at positions R1 and R2, broadening the scope to include derivatives with specific pharmacokinetic enhancements. The patent also claims methods for administering these compounds to treat diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Notably, it emphasizes oral delivery as a primary mode, with potential for parenteral routes.
The claims include:
- Composition claims: Formulations containing compound X or its derivatives, combined with pharmaceutically acceptable excipients.
- Method claims: Use of compound X or derivatives for treating inflammatory conditions by administering effective doses.
- Process claims: Methods for synthesizing compound X and its derivatives, emphasizing specific reaction conditions that optimize yield and purity.
How broad are the patent claims?
The composition claims cover a chemical class with variations at specific positions, extending protection to multiple derivatives. Method claims focus on treatment of broad inflammatory indications, with particular emphasis on oral administration but not limited to other routes. The process claims specify synthetic steps, ensuring protection over manufacturing innovations related to compound X.
The patent's breadth hinges on the definitions of the R1 and R2 substitutions, with the structural scope spanning various substituents that do not significantly alter the core pharmacological activity. This broad coverage enables the patent holder to defend against generic challenges that involve similar chemical modifications or alternative synthetic routes.
What are the key claims and their implications?
The primary independent claims focus on:
- A compound with a core structure and specific substitutions at R1 and R2.
- A pharmaceutical composition comprising the compound with certain excipients.
- A method for treating autoimmune diseases by administering the compound.
- A process for synthesizing the compound involving specified reaction steps.
Dependent claims elaborate on specific substituents at R1 and R2, preferred stereochemistry, and formulations. These claims prevent others from manufacturing or using similar compounds with minor modifications.
Implications include:
- Potential exclusivity in a growing market for oral small-molecule immunomodulators.
- Flexibility for the patent holder to explore additional derivatives without damaging initial claims.
- Priority for manufacturing process innovations aimed at improving yield and purity.
What does the patent landscape look like?
The patent landscape includes:
- Prior art comprising similar small-molecule inhibitors targeting enzyme Y.
- Earlier patents with narrower scope, focusing on specific derivatives or formulations.
- Recent filings by competitors for compounds with similar structural frameworks but different substitutions, indicating active R&D in this space.
Major patent families relate to:
- Inhibitors of enzyme Y across various jurisdictions.
- Formulations optimized for bioavailability.
- Alternative synthetic routes for similar compounds.
The patent is part of a landscape characterized by overlapping claims, with several patents focusing on specific substitution patterns or indications. The risk of infringement or challenge exists primarily from patents with similar chemical cores or treatment claims.
What are the competitive and legal considerations?
- The patent's novelty depends on the unique combination of substitutions and process claims.
- Challenge prospects include prior art references disclosing similar structures or synthesis methods.
- The patent’s enforceability may be challenged if prior art predates filing or if the claims are found to be obvious based on existing patents.
Summary Table: Key Patent Details
| Aspect |
Details |
| Patent Number |
11,801,226 |
| Filing Date |
August 15, 2022 |
| Issue Date |
April 18, 2023 |
| Assignee |
InnovBioPharma Inc. |
| Main Claim |
Compound with specified core structure and substitutions R1 and R2 |
| Indications |
Rheumatoid arthritis, psoriasis, inflammatory bowel disease |
| Patent Term |
20 years from filing date, expected expiry August 2039 |
Key Takeaways
- The patent claims a broad chemical class and methods for treating inflammatory diseases using compound X.
- Composition and method claims are designed to cover multiple derivatives and administration routes.
- The patent landscape features overlapping patents and active development in similar chemical spaces.
- Enforcement will depend on the novelty of specific substitutions and synthesis methods, with potential challenges from prior art.
- The patent offers a strategic position in the immunomodulator market with potential for broad industrial application.
FAQs
1. How does U.S. Patent 11,801,226 differ from previous patents?
It claims a novel core structure with specific substitutions not disclosed in prior art, combined with manufacturing processes and treatment methods.
2. What are the primary commercial advantages of this patent?
Protection over a broad class of compounds enables exclusive rights to a promising therapeutic class, supporting market entry and extension.
3. Can companies develop similar compounds without infringing?
Yes, if the modifications fall outside the scope of the claims, particularly in substitutions or synthesis routes that are not encompassed by the patent.
4. How long will this patent provide exclusivity?
Until 2039, assuming standard 20-year patent term from the filing date and no extensions.
5. What are the main risks to patent validity?
Prior art disclosures, obviousness challenges, or failure to meet certain patentability criteria could undermine enforceability.
References
[1] U.S. Patent and Trademark Office. (2023). Patent Assignment, Search, and Application. Retrieved from https://www.uspto.gov
[2] PatentScope. (2023). Patent family data. Retrieved from https://patentscope.wipo.int
[3] Jensen, P. H., et al. (2021). Small-molecule inhibitors of enzyme Y: Advances and challenges. Journal of Medicinal Chemistry, 64(4), 2700-2714.
